{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:26Z","timestamp":1740147266048,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pseudomyxoma Peritonei (PMP) is a severe neoplastic clinical syndrome characterised by secretion of mucin from tumors often originating in the appendix. The standard treatment includes cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). A new perspective in PMP treatment aims at the mucins themselves as a therapeutic target.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Here we report the first case of PMP with peritoneal dissemination of mucinous implants caused by low-grade appendiceal mucinous neoplasm (LAMN) in a 58-year-old white male exclusively treated by appendectomy and oral administration of bromelain and acetylcysteine in the context of a medical self-experimentation (by co-author T.R.). Observation so far covers a period of 48\u00a0months including regular magnetic resonance imaging (MRI) with stable findings.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Oral administration of bromelain and acetylcysteine can be used in the treatment of PMP caused by LAMN without relevant clinical side effects.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04024-7","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:01:51Z","timestamp":1687996911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-0971","authenticated-orcid":false,"given":"Dominik","family":"Geisel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Langen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"R\u00fcdiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"4024_CR1","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/ans.16185","volume":"90","author":"ML Soucisse","year":"2020","unstructured":"Soucisse ML, Lansom J, Alshahrani MS, Morris DL. Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. ANZ J Surg. 2020;90:1888\u201394. https:\/\/doi.org\/10.1111\/ans.16185.","journal-title":"ANZ J Surg"},{"key":"4024_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000354425","volume":"29","author":"B Rau","year":"2013","unstructured":"Rau B, Kilian M, K\u00f6hler C, Mangler M, von Winterfeld M, Rudl M, Raue W. Indikationen und Resultate der Peritonektomie bei nichtkolorektaler Peritonealkarzinose. Viszeral Gastrointest Med Surg. 2013;29:235\u201344. https:\/\/doi.org\/10.1159\/000354425.","journal-title":"Viszeral Gastrointest Med Surg"},{"key":"4024_CR3","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156:e206363. https:\/\/doi.org\/10.1001\/jamasurg.2020.6363.","journal-title":"JAMA Surg"},{"key":"4024_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/bjs5.97","volume":"3","author":"F Mercier","year":"2019","unstructured":"Mercier F, Dagbert F, Pocard M, Go\u00e9r\u00e9 D, Qu\u00e9net F, Wernert R, Dumont F, Brigand C, Passot G, Gl\u00e9hen OJ. on behalf of the RENAPE Network: recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. 2019;3:195\u2013202. https:\/\/doi.org\/10.1002\/bjs5.97.","journal-title":"BJS Open"},{"key":"4024_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-9-71","volume":"9","author":"A Amini","year":"2014","unstructured":"Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet J Rare Dis. 2014;9:71. https:\/\/doi.org\/10.1186\/1750-1172-9-71.","journal-title":"Orphanet J Rare Dis"},{"key":"4024_CR6","doi-asserted-by":"publisher","first-page":"7909","DOI":"10.2147\/CMAR.S324982","volume":"13","author":"Y-L Lin","year":"2021","unstructured":"Lin Y-L, Li Y. The biological synthesis and the function of mucin 2 in pseudomyxoma peritonei. Cancer Manage Res. 2021;13:7909\u201317. https:\/\/doi.org\/10.2147\/CMAR.S324982.","journal-title":"Cancer Manage Res"},{"key":"4024_CR7","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1007\/s10637-012-9797-7","volume":"30","author":"K Pillai","year":"2012","unstructured":"Pillai K, Akhter J, Chua TC, Morris DL. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei. Invest New Drugs. 2012;30:2080\u20136. https:\/\/doi.org\/10.1007\/s10637-012-9797-7.","journal-title":"Invest New Drugs"},{"key":"4024_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ijc.28380","volume":"134","author":"K Pillai","year":"2014","unstructured":"Pillai K, Akhter J, Chua TC, Morris DL. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. Int J Cancer. 2014;134:478\u201386. https:\/\/doi.org\/10.1002\/ijc.28380.","journal-title":"Int J Cancer"},{"key":"4024_CR9","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.3390\/cancers13235965","volume":"13","author":"A Sommariva","year":"2021","unstructured":"Sommariva A, Tonello M, Rigotto G, Lazzari N, Pilati P, Calabr\u00f2 ML. Novel perspectives in pseudomyxoma peritonei treatment. Cancers. 2021;13:5965. https:\/\/doi.org\/10.3390\/cancers13235965.","journal-title":"Cancers"},{"key":"4024_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-28570-2","volume-title":"Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies","author":"A Amini","year":"2016","unstructured":"Amini A, Masoumi-Moghaddam S, Morris DL. Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Cham: Springer; 2016. https:\/\/doi.org\/10.1007\/978-3-319-28570-2."},{"key":"4024_CR11","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/PL00000936","volume":"58","author":"HR Maurer","year":"2001","unstructured":"Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001;58:1234\u201345. https:\/\/doi.org\/10.1007\/PL00000936.","journal-title":"Cell Mol Life Sci"},{"key":"4024_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejso.2019.10.033","volume":"47","author":"SJ Valle","year":"2021","unstructured":"Valle SJ, Akhter J, Mekkawy AH, Lodh SP, Pillai K, Badar S, Glenn D, Power MA, Liauw W, Morris DL. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. Eur J Surg Oncol. 2021;47:115\u201322. https:\/\/doi.org\/10.1016\/j.ejso.2019.10.033.","journal-title":"Eur J Surg Oncol"},{"key":"4024_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1245\/s10434-021-10372-9","volume":"29","author":"\u00c1 Arjona-S\u00e1nchez","year":"2022","unstructured":"Arjona-S\u00e1nchez \u00c1, Mart\u00ednez-L\u00f3pez A, Valenzuela-Molina F, Rufi\u00e1n-And\u00fajar B, Rufi\u00e1n-Pe\u00f1a S, Casado-Adam \u00c1, S\u00e1nchez-Hidalgo JM, Rodr\u00edguez-Ortiz L, Medina-Fern\u00e1ndez FJ, D\u00edaz-L\u00f3pez C, et al. A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei. Ann Surg Oncol. 2022;29:126\u201336. https:\/\/doi.org\/10.1245\/s10434-021-10372-9.","journal-title":"Ann Surg Oncol"},{"key":"4024_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.humpath.2021.04.007","volume":"113","author":"EP Ward","year":"2021","unstructured":"Ward EP, Okamuro L, Khan S, Hosseini M, Valasek MA, Ronquillo N Jr, Kelly KJ, Veerapong J, Lowy AM, Baumgartner J. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC. Hum Pathol. 2021;113:104\u201310. https:\/\/doi.org\/10.1016\/j.humpath.2021.04.007.","journal-title":"Hum Pathol"},{"key":"4024_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1245\/s10434-013-3283-0","volume":"21","author":"FSW Zih","year":"2014","unstructured":"Zih FSW, Wong-Chong N, Hummel C, Petronis J, Panzarella T, Pollett A, McCart JA, Swallow CJ. Mucinous tumor of the appendix with limited peritoneal spread: is there a role for expectant observation? Ann Surg Oncol. 2014;21:225\u201331. https:\/\/doi.org\/10.1245\/s10434-013-3283-0.","journal-title":"Ann Surg Oncol"},{"key":"4024_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12672-021-00418-5","volume":"12","author":"K Ke","year":"2021","unstructured":"Ke K, Pillai K, Mekkawy AH, Akhter J, Badar S, Valle SJ, Morris DL. The effect of intraperitoneal administration of BromAc\u00ae on blood parameters: phase 1 study. Discov Oncol. 2021;12:25. https:\/\/doi.org\/10.1007\/s12672-021-00418-5.","journal-title":"Discov Oncol"},{"key":"4024_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/COC.0000000000000878","volume":"45","author":"M Vierra","year":"2022","unstructured":"Vierra M, Dhiman A, Witmer HDD, Ulrich L, Hindi E, Fenton E, Shergill A, Polite B, Eng OS, Turaga KK. Celecoxib and Myrtol\u2014a novel therapy for recurrent appendiceal mucinous neoplasms with extensive peritoneal dissemination. Am J Clin Oncol Cancer Clin Trials. 2022;45:9\u201313. https:\/\/doi.org\/10.1097\/COC.0000000000000878.","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"4024_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21037\/cco-21-2","volume":"10","author":"S Hirano","year":"2021","unstructured":"Hirano S, Gohda Y, Miyazaki H, Hayama N, Shimizu S, Igari T, Yano H. A case of pseudomyxoma peritonei successfully treated with trifluridine\/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery. Chin Clin Oncol. 2021;10:29. https:\/\/doi.org\/10.21037\/cco-21-2.","journal-title":"Chin Clin Oncol"},{"key":"4024_CR19","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1159\/000514273","volume":"14","author":"AR Lam","year":"2021","unstructured":"Lam AR, Bazzi K, Valle SJ, Morris DL. Novel use of bromelain and acetylcysteine (BromAc\u00ae) for pleural involvement in pseudomyxoma peritonei. Case Rep Oncol. 2021;14:628\u201333. https:\/\/doi.org\/10.1159\/000514273.","journal-title":"Case Rep Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04024-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:02:45Z","timestamp":1687996965000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4024"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04024-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (case report) has been performed with an appropriate participants\u2019 informed consent in compliance with the\u00a0World Medical Association Declaration of Helsinki. Informed consent for publication of the medical case details and accompanying images can be inferred from the patient being one of the co-authors (Thomas R\u00fcdiger, M.D.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"297"}}